APA (7th ed.) Citation

Cloughesy, T., van den Bent, M. J., Touat, M., Blumenthal, D. T., Peters, K. B., Ellingson, B. M., . . . Mellinghoff, I. K. (2025). Vorasidenib in IDH1-mutant or IDH2-mutant low-grade glioma (INDIGO): Secondary and exploratory endpoints from a randomised, double-blind, placebo-controlled, phase 3 trial. The lancet. Oncology, 26(12), . https://doi.org/10.1016/S1470-2045(25)00472-3

Chicago Style (17th ed.) Citation

Cloughesy, Timothy, et al. "Vorasidenib in IDH1-mutant or IDH2-mutant Low-grade Glioma (INDIGO): Secondary and Exploratory Endpoints from a Randomised, Double-blind, Placebo-controlled, Phase 3 Trial." The Lancet. Oncology 26, no. 12 (2025). https://doi.org/10.1016/S1470-2045(25)00472-3.

MLA (9th ed.) Citation

Cloughesy, Timothy, et al. "Vorasidenib in IDH1-mutant or IDH2-mutant Low-grade Glioma (INDIGO): Secondary and Exploratory Endpoints from a Randomised, Double-blind, Placebo-controlled, Phase 3 Trial." The Lancet. Oncology, vol. 26, no. 12, 2025, https://doi.org/10.1016/S1470-2045(25)00472-3.